Multicentre Phase II Trial Evaluating Stereotactic Body Radiotherapy on Ultra-central Lung Tumors on MR-Linac (LIN-LUNG-2504)
Multicentre Phase II Trial Evaluating Stereotactic Body Radiotherapy (SBRT) on Ultra-central Lung Tumors on MR-Linac (Magnetic Resonance Image-Guided Radiotherapy)
연구 개요
상태
정황
개입 / 치료
상세 설명
This interventional, prospective, multicenter, non-randomized Phase II study primarily aims to evaluate the safety of MRI-guided stereotactic radiotherapy delivered with an MRI-LINAC, particularly in terms of late toxicity of grade ≥3.
Ultracentral lung tumors represent a major therapeutic challenge due to their immediate proximity to critical structures such as the tracheobronchial tree, oesophagus, and pericardium. This location exposes patients to an increased risk of severe complications (haemorrhage, fistula, stenosis, pneumonitis), limiting the doses that can be delivered with conventional radiotherapy and potentially compromising tumor control.
The use of an MRI-LINAC enables real-time visualization of anatomical structures and adaptation of the treatment plan at each session (adaptive radiotherapy). This technology also incorporates respiratory motion management systems (gating), allowing for reduced treatment margins and improved sparing of organs at risk.
Enrolled patients will receive stereotactic radiotherapy delivered in 8 fractions, with extended clinical, radiological, and functional follow-up.
In addition to assessing late toxicity, the study will also evaluate the feasibility of the technique, early adverse events, overall survival, progression-free survival, tumor control, and changes in respiratory function.
The overall objective is to demonstrate that MRI-LINAC-guided radiotherapy can reduce toxicity while maintaining satisfactory tumor control in this high-risk population, thereby improving the management of ultracentral lung tumors.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Florence LE TINIER, MD
연구 연락처 백업
- 이름: Alicia PROBST, PhD
- 전화번호: +33 (0)3 20 29 59 18
- 이메일: promotion@o-lambret.fr
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age ≥ 18 year-old
Clinical status:
- Primary lung tumour T1-T2 N0, confirmed histologically by bronchoscopic examination, or meeting the criteria set out in the Aura 2026 and ASTRO guidelines for the indication of stereotactic radiotherapy (tumor growth of at least 2 mm between two CT scans performed 3 months apart, metabolic hyper-intensity on PET, and no pathological evidence), OR
- Metachronous oligometastatic disease: isolated mediastinal or non-central pulmonary lymph node recurrence occurring sometimes after initial cancer treatments for an initially localised, locally advanced or oligometastatic cancer that has been treated OR
- Synchronous oligometastatic disease: all metastatic sites and the primary tumour must be amenable to local debulking treatment following systemic treatment. Systemic treatment (chemotherapy or targeted therapy) must not be administered concurrently with radiotherapy OR
- Metachronous oligoprogression: isolated metastatic recurrence in the mediastinal or ultra-central lung lymph nodes, with the primary tumour and metastatic sites under control (no change observed on two consecutive imaging scans and a complete metabolic response on PET) and not requiring continued treatment with chemotherapy or targeted therapy to ensure disease control (hormone therapy is, however, permitted)
- Patient unsuitable for surgery, and treatment with stereotactic RT validated by multidisciplinary tumor board (including the radiation oncologist and medical physician)
- Ultracentral lesion defined by a GTV less than 1 cm of the PBT (proximal bronchial trachea, including the main bronchi, trachea and intermediate bronchi), oesophagus, or pericardum
- ECOG performance status ≤2 (for all patients)
- Patient covered by a health insurance system
- Patient agreed to take part in the study, and signed an informed consent form
- Use of a method of contraception (for female patients of childbearing age)
Exclusion Criteria:
- Tumour with intrabronchial or intratracheal invasion identified by fibroscopy, bronchoscopy or localisation MRI
- Prior RT overlapping the intended treatment field
- Patients with oligoprogression requiring continued systemic treatment during RT
- Uncontrolled intercurrent diseases
- Contraindication to radiotherapy due to a comorbidity such as pulmonary fibrosis or scleroderma
- Respiratory contraindications (FEV1 < 20%)
- Need of oncologic systemic treatment during RT
- Contraindication to MRI (e.g. severe claustrophobia unmanageable)
- Pregnancy or breastfeeding patient
- Patient under guardianship or curatorship
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: MR-guided stereotactic radiotherapy (MR-LINAC)
|
Stereotactic body radiotherapy (SBRT) is delivered using an MRI-guided linear accelerator (MR-LINAC), at a total dose of 60 Gy in 8 fractions (7.5 Gy per fraction) over 17 days.
Treatment is performed using MR-guided adaptive radiotherapy with real-time imaging and respiratory motion management (gating).
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of late treatment-related toxicity
기간: from 90 days post-radiotherapy to 36 months after end of treatment
|
Treatment-related toxicity is assessed according to NCI-CTCAE v6.0 and defined as grade ≥ 3 adverse events such as: pneumonitis, bronchopulmonary haemorrhage, fibrosis, airway obstruction, fistula, or oesophageal toxicity, or other severe toxicity. Death possibly related to radiotherapy within 36 months is also considered as an event. |
from 90 days post-radiotherapy to 36 months after end of treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Early and late adverse events (all grades)
기간: From radiotherapy simulation up to 36 months post-radiotherapy
|
Early and late adverse events are assessed according to NCI-CTCAE v6.0.
Adverse events that are definitively linked to the underlying disease, the progression of the underlying disease, or systemic treatment are excluded.
|
From radiotherapy simulation up to 36 months post-radiotherapy
|
|
Feasibility of MR-guided radiotherapy
기간: from treatment initiation up to 3 months after completion of radiotherapy
|
Feasibility of MR-guided radiotherapy is evaluated considering occurrence of primary failures (patient who dindn't start treatment) or secondary failures (incomplete treatment, or significant interruption of more than one week).
|
from treatment initiation up to 3 months after completion of radiotherapy
|
|
Progression-Free Survival (PFS)
기간: from treatment initiation to progression or death, assessed up to 36 months
|
Time from treatment initiation to disease progression (local, regional, or distant) or death from any cause
|
from treatment initiation to progression or death, assessed up to 36 months
|
|
Overall Survival (OS)
기간: from treatment initiation up to 36 months
|
Time from treatment initiation to death from any cause.
|
from treatment initiation up to 36 months
|
|
Local, regional, and distant disease control
기간: at 6, 12, 24, and 36 months after treatment
|
Assessed using imaging-based evaluation and cumulative incidence of progression.
|
at 6, 12, 24, and 36 months after treatment
|
|
FEV1 lung test
기간: at baseline, and at 6, 18, and 30 months post-treatment
|
This test evaluates forced expiratory volume in one second
|
at baseline, and at 6, 18, and 30 months post-treatment
|
|
Dosimetric parameters related to target coverage (GTV, CTV, PTV)
기간: During treatment planning (less than 30 days after enrollment), and then at each radiotherapy session (8 sessions spaced 2 days apart over a period of 17 days). Radiotherapy should start no later than 30 days after enrollment. .
|
Gross Tumor Volume (GTV), Clinical Target Volume (CTV), and Planning Target Volume (PTV) are evaluated, and recorded during treatment planning, and at each adaptive fraction to document the benefit of online plan adaptation enabled by the MR-LINAC technology.
|
During treatment planning (less than 30 days after enrollment), and then at each radiotherapy session (8 sessions spaced 2 days apart over a period of 17 days). Radiotherapy should start no later than 30 days after enrollment. .
|
|
Radiation dose delivered to CTV and OAR
기간: During treatment planning (less than 30 days after enrollment), and then at each radiotherapy session (8 sessions spaced 2 days apart over a period of 17 days). Radiotherapy should start no later than 30 days after enrollment.
|
The radiation dose delivered (Gy) to the clinical target volume (CTV) and healthy nearby tissues (OAR, Organs at Risk) is evaluated, and recorded during treatment planning, and at each adaptive fraction, to document the benefit of online plan adaptation enabled by the MR-LINAC technology.
|
During treatment planning (less than 30 days after enrollment), and then at each radiotherapy session (8 sessions spaced 2 days apart over a period of 17 days). Radiotherapy should start no later than 30 days after enrollment.
|
|
Lung diffusion test (DLCO)
기간: at baseline, and at 6, 18, and 30 months post-treatment
|
The DLCO test measures how effectively the lungs transfer oxygen from inhaled air to the blood
|
at baseline, and at 6, 18, and 30 months post-treatment
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Florence LE TINIER, MD, Centre Oscar Lambret, Lille
- 연구 책임자: David PASQUIER, MD, PhD, Centre Oscar Lambret, Lille
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .